FDA once again jilts Xarelto

| | Cardiovascular Business | Structural Heart Disease

The FDA has issued a second complete response letter on a supplemental New Drug Application (sNDA) for rivaroxaban for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS).

In early 2012, Janssen Research & Development received a priority review designation from the FDA for rivaroxaban (Xarelto) to reduce the risk of secondary cardiovascular events in patients with ACS. But in May, the FDA’s Cardiovascular and Renal Drugs Advisory Committee recommended against approval after a debate about the results of the ATLAS ACS 2 TIMI trial that mainly focused on missing data and bleeding risks.

The FDA issued its first sNDA in June and in September, Janssen submitted its reply, including data from the ATLAS ACS 2 TIMI 51 trial.

Raritan, N.J.-based Janssen said it is evaluating the second letter and will respond to the FDA’s questions.

Related Content

How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
9 key takeaways from AHA 2024 in Chicago
Redo TAVR: The impact of implanting balloon-expandable valves in failed self-expanding valves
Edoxaban could limit blood clots, ‘make life easier’ for heart valve surgery patients

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."